蛋白质糖基化修饰:新一代肝病靶标的分子基础  

Glycosylated modification of protein is the molecular basis of new targets in liver diseases

作　　者：常路丝[1] 乔雍[1] 魏红山[1] 

机构地区：[1]首都医科大学附属北京地坛医院,北京100015

出　　处：《胃肠病学和肝病学杂志》2011年第4期302-305,共4页Chinese Journal of Gastroenterology and Hepatology

基　　金：国家自然科学基金资助(No.30671875;No.30872243)

摘　　要：肝病糖生物学研究是新一代肝病分子诊断标志物及肝癌治疗分子靶点研究的热点领域。不同肝病过程中伴随着复杂的蛋白质N-糖基化和O-糖基化修饰,这些糖基化修饰的变化导致了一些蛋白质翻译后修饰的改变,因而有可能成为未来新的肝病诊断标志物。这些修饰聚糖改变的基础在于肝细胞内部糖基转移酶和糖苷酶活性的变化,因而,对糖基转移酶和糖苷酶活性调控也有可能成为新一代抗癌药物研发的靶点。针对血清蛋白N-糖组分析也已经成为肝癌、肝硬化诊断的新方法。这些进展预示着肝病糖生物学研究将迎来一个新的时代。The field of liver disease glycobiology is a new area of molecular target in liver disease.With the progression of disease,the glycosylation of protein results in complex modification of post-translation.The variations of glycan are consistent with activity of glycosyltransferase and glycolysase.Consequently,the glycosyltransferase and glycosylase related with liver disease may be a new treatment target of hepaticellular carcinma.The serum N-glycome analysis is a new method for diagnosing liver cirrhosis and hepaticellular carcinoma.These progressions suggest that a new era of liver glycobiology is coming.

关 键 词：肝癌 糖基化 糖基转移酶 糖组 糖型 N-聚糖糖谱 

分 类 号：R575[医药卫生—消化系统]